MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J R Ebert, Jeanne Cheung, Yagai Yang, Erin McNamara, Rebecca Hong, Marina Moskalenko, Stephen E Gould, Heather Maecker, Bryan A Irving, Jeong M Kim, Marcia Belvin, Ira Mellman, Peter J R Ebert, Jeanne Cheung, Yagai Yang, Erin McNamara, Rebecca Hong, Marina Moskalenko, Stephen E Gould, Heather Maecker, Bryan A Irving, Jeong M Kim, Marcia Belvin, Ira Mellman
Abstract
Targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) can induce regression of tumors bearing activating mutations in the Ras pathway but rarely leads to tumor eradication. Although combining MEK inhibition with T-cell-directed immunotherapy might lead to more durable efficacy, T cell responses are themselves at least partially dependent on MEK activity. We show here that MEK inhibition did profoundly block naive CD8(+) T cell priming in tumor-bearing mice, but actually increased the number of effector-phenotype antigen-specific CD8(+) T cells within the tumor. MEK inhibition protected tumor-infiltrating CD8(+) T cells from death driven by chronic TCR stimulation while sparing cytotoxic activity. Combining MEK inhibition with anti-programmed death-ligand 1 (PD-L1) resulted in synergistic and durable tumor regression even where either agent alone was only modestly effective. Thus, despite the central importance of the MAP kinase pathway in some aspects of T cell function, MEK-targeted agents can be compatible with T-cell-dependent immunotherapy.
Copyright © 2016 Elsevier Inc. All rights reserved.
Source: PubMed